HTG Molecular Diagnostics, Inc. (HTGM) Comparison with companies in other sectors?

HTG Molecular Diagnostics, Inc. has a share price of 2.21M. You can analyze HTG Molecular Diagnostics, Inc. (HTGM) competitors across different market sectors through stock heatmaps.

What are HTGM's NET and operating margins?

HTG Molecular Diagnostics, Inc. (HTGM) operating margin is around -3.27, and net profit margin is approximately -3.39 as of the latest reports.

In what way does HTGM's earnings per share (EPS) trend reflect its financial momentum?

HTG Molecular Diagnostics, Inc. (HTGM) EPS is -17.10 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for HTG Molecular Diagnostics, Inc. is -0.03, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for HTG Molecular Diagnostics, Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for HTG Molecular Diagnostics, Inc. like P/E which is -0.02, P/B which is 0.08, and PEG which is -0.00. Compare them with sector averages to evaluate if the stock is priced fairly.

HTG Molecular Diagnostics, Inc.

HTGM•NASDAQ

Healthcare

Medical - Diagnostics & Research

$0.48

$0.00(0.00%)

Fundamental Analysis of HTG Molecular Diagnostics, Inc. (HTGM)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-17.10

P/E Ratio

-0.03

ROE

-2.73%

Net Margin

-3.39%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$1.06M

Shares OutstandingTotal number of shares issued

$2.21M

Book Value/ShareNet worth per share

$6.06

Revenue/ShareAnnual revenue per share

$7.16

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-17.1

Net MarginNet income as percentage of revenue

-339.20%

Operating MarginOperating income as percentage of revenue

-327.19%

ROEReturn on shareholders' equity

-273.49%

ROAReturn on total assets

-121.47%

ROCEReturn on capital employed

-219.10%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-20.73

Cash/ShareCash and equivalents per share

$13.73

FCF YieldFree cash flow as percentage of market cap

-1734.13%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for HTGMFinancial Ratios Analysis details for HTGM are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for HTGMSector Benchmarking details for HTGM are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for HTG Molecular Diagnostics, Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of HTG Molecular Diagnostics, Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account HTG Molecular Diagnostics, Inc.'s unique business strengths and challenges.

Key Financial Metrics for HTG Molecular Diagnostics, Inc.

For HTG Molecular Diagnostics, Inc., essential financial indicators include EPS -17.10, PE -0.03, and ROE -2.73. These key ratios reveal insights into HTG Molecular Diagnostics, Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare HTG Molecular Diagnostics, Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of HTG Molecular Diagnostics, Inc.

Metrics like Net Margin -339.20% and ROA -121.47% shed light on how well HTG Molecular Diagnostics, Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether HTG Molecular Diagnostics, Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of HTG Molecular Diagnostics, Inc.

Using ratios such as P/B Ratio 0.08 and PEG Ratio -0.00, investors can assess whether HTG Molecular Diagnostics, Inc. is appropriately valued based on its financials and growth potential. These figures, combined with HTG Molecular Diagnostics, Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for HTG Molecular Diagnostics, Inc.

Financial health indicators, such as Debt/Equity Ratio 0.90 and Cash Flow $-20.73, provide a snapshot of HTG Molecular Diagnostics, Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like HTG Molecular Diagnostics, Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for HTG Molecular Diagnostics, Inc.

Investing in HTG Molecular Diagnostics, Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at HTG Molecular Diagnostics, Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;